Celularity Inc. CELU

CELU Company Overview

Celularity Inc. is a U.S.-based biotechnology company focused on the development of cellular medicines, biomaterial products, and regenerative medicine technologies derived primarily from the human placenta. The company operates within the biotechnology, immunotherapy, and regenerative medicine industries, with a strategic emphasis on allogeneic cell therapies designed to treat cancer, infectious diseases, and degenerative conditions. Celularity’s primary revenue sources have included biomaterial product sales, licensing arrangements, collaborative agreements, and regenerative medicine-related commercial activities, while its therapeutic pipeline remains largely in the clinical and development stages.

The company traces its origins to research and commercialization initiatives associated with placental-derived cells and tissues developed under Celgene Corporation’s cellular therapeutics efforts. Celularity later became an independent company and entered public markets through a merger with a special purpose acquisition company in 2021. Its positioning has centered on the scalability and immunologic characteristics of placental-derived allogeneic therapies, which the company has described as potentially enabling off-the-shelf treatment approaches compared with patient-specific autologous therapies.